Ovid Therapeutics Reports Q3 2026 Net Loss of $20.8 Million and $161.4 Million in Cash
Ovid Therapeutics reported a Q3 2026 net loss of $20.8M, up from $12.2M a year earlier, due to increased R&D spending. The company had $161.4M in cash and expects its runway to extend into 2029. Ovid is advancing clinical studies for OV329 and OV4071, with data readouts anticipated in early 2027.



